Compare JCE & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JCE | PBYI |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.8M | 263.4M |
| IPO Year | N/A | N/A |
| Metric | JCE | PBYI |
|---|---|---|
| Price | $15.92 | $6.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 49.7K | ★ 387.6K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 9.26% | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $211,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.87 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.64 | $2.58 |
| 52 Week High | $14.28 | $6.27 |
| Indicator | JCE | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 60.41 |
| Support Level | $15.39 | $5.64 |
| Resistance Level | $16.14 | $6.27 |
| Average True Range (ATR) | 0.20 | 0.24 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 70.67 | 67.72 |
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.